May 02, 2023 / 02:30PM GMT
Joe Pantginis - H.C. Wainwright & Co., LLC - Analyst
Good morning, everybody. I think we're still at morning. Yes, we are. Welcome back to H.C. Wainwright's third Annual BioConnect Conference. My name is Joe Pantginis. I'm the Director of Research and Managing Director here at the firm. Pleasure to have with us for our next fireside chat, XOMA. Presenting for the company is Owen Hughes, the Executive Chair; and Brad Sitko, the Chief Investment Officer.
And before we dive in, I'd say, essentially, I have covered every iteration of XOMA, I believe, back when it was a drug development company to what you are now. And I would say that going back several years ago when we had our global conference in Monaco, was one of the first times that Jim Neal, who is now retired, really presented your new strategy of royalty aggregator. And I'd say from between then and now, you've really solidified the thesis. So I give you my own congratulations for that.
Questions and Answers:
Joe Pantginis - H.C. Wainwright & Co., LLC - AnalystSo I guess, let's just
Trustpilot
